Schildkraut JM - Search Results

1

Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer.

Schildkraut JM, Murphy SK, Palmieri RT, Iversen E, Moorman PG, Huang Z, Halabi S, Calingaert B, Gusberg A, Marks JR, Berchuck A. Schildkraut JM, et al. Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):473-80. doi: 10.1158/1055-9965.EPI-06-0868. Cancer Epidemiol Biomarkers Prev. 2007. PMID: 17372242

2

Oral contraceptive pills. Prevention of ovarian cancer and other benefits.

Berchuck A, Schildkraut J. Berchuck A, et al. N C Med J. 1997 Nov-Dec;58(6):404-7; discussion 408. N C Med J. 1997. PMID: 9392951 Review.

3

Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history.

Claus EB, Schildkraut J, Iversen ES Jr, Berry D, Parmigiani G. Claus EB, et al. J Natl Cancer Inst. 1998 Dec 2;90(23):1824-9. doi: 10.1093/jnci/90.23.1824. J Natl Cancer Inst. 1998. PMID: 9839523

4

Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2.

Bluman LG, Rimer BK, Berry DA, Borstelmann N, Iglehart JD, Regan K, Schildkraut J, Winer EP. Bluman LG, et al. J Clin Oncol. 1999 Mar;17(3):1040-6. doi: 10.1200/JCO.1999.17.3.1040. J Clin Oncol. 1999. PMID: 10071299 Clinical Trial.

5

Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk.

Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Schildkraut JM, et al. J Natl Cancer Inst. 2002 Jan 2;94(1):32-8. doi: 10.1093/jnci/94.1.32. J Natl Cancer Inst. 2002. PMID: 11773280

6

Pre-counseling education materials for BRCA testing: does tailoring make a difference?

Skinner CS, Schildkraut JM, Berry D, Calingaert B, Marcom PK, Sugarman J, Winer EP, Iglehart JD, Futreal PA, Rimer BK. Skinner CS, et al. Among authors: schildkraut jm. Genet Test. 2002 Summer;6(2):93-105. doi: 10.1089/10906570260199348. Genet Test. 2002. PMID: 12215248

7

Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States).

Moorman PG, Schildkraut JM, Calingaert B, Halabi S, Vine MF, Berchuck A. Moorman PG, et al. Among authors: schildkraut jm. Cancer Causes Control. 2002 Nov;13(9):807-11. doi: 10.1023/a:1020678100977. Cancer Causes Control. 2002. PMID: 12462545

8

High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival.

Lancaster JM, Sayer R, Blanchette C, Calingaert B, Whitaker R, Schildkraut J, Marks J, Berchuck A. Lancaster JM, et al. Among authors: schildkraut j. Clin Cancer Res. 2003 Feb;9(2):762-6. Clin Cancer Res. 2003. PMID: 12576447

9

No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina.

Lancaster JM, Wenham RM, Halabi S, Calingaert B, Marks JR, Moorman PG, Bentley RC, Berchuck A, Schildkraut JM. Lancaster JM, et al. Among authors: schildkraut jm. Cancer Epidemiol Biomarkers Prev. 2003 Mar;12(3):226-7. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 12646513 No abstract available.

10

Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls.

Vine MF, Calingaert B, Berchuck A, Schildkraut JM. Vine MF, et al. Among authors: schildkraut jm. Gynecol Oncol. 2003 Jul;90(1):75-82. doi: 10.1016/s0090-8258(03)00175-6. Gynecol Oncol. 2003. PMID: 12821345

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

377 results

Search Page

Filters